Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Lung Diseases, Interstitial Clinical Trial

Official title:

A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase 2/3 Study of Efficacy and Safety of Olokizumab in Subjects With Progressive Fibrosing Interstitial Lung Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06440746
• Other study ID #: CL04041109
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: August 23, 2023
• Est. completion date: December 5, 2026

Study information

• Verified date: May 2024
• Source: R-Pharm
• Contact: Yana Deloveri
• Phone: + 7 (968) 585-13-49
• Email: deloveri[@]rpharm.ru
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).

Description:

This is a phase 2/3 study with double-blind parallel-group adaptive design.

The study will include the following periods:

1. Screening period (4 weeks) Screening period (before the first administration of the test drug). Before being included in the study, patients will be provided with complete information about this clinical trial and signs the Informed consent Form (IF). After that the researcher will decide whether or not the patient can be randomized into the study.

2. Double-blind Treatment period (48 weeks). Following the completion of a Treatment period, all patients will be enrolled in Follow-up Period (FU).

3. Follow-up Period (24 weeks). During the FU Period, patients will visit study sites after 4,12 and 24 weeks after the end of the Treatment Period to complete FU-1 (Week 52), FU-2 (Week 60) and FU-3 (Week 72) visits.

The overall study duration for the patients will be approximately 76 weeks (including the 4 weeks screening period)

The analysis will be conducted in two sequential steps:

• the interim analysis after 60 percent (%) of patients have completed the Treatment period (not including the FU period)

• the final analysis when all patients have completed all periods (the Treatment and the FU periods).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 116
• Est. completion date: December 5, 2026
• Est. primary completion date: June 20, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient has signed the Informed Consent Form

2. Progressive fibrosing ILD confirmed by high-resolution computed tomography (HRCT) documented evidence of >10% lung tissue affected at Screening:

A. Patients with an usual interstitial pneumonia (UIP) -like radiological pattern described in the 2022 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines for the management Idiopathic pulmonary fibrosis (IPF) that do not have an identified primary condition

?. Patients with progressive interstitial pneumonia with autoimmune features (IPAF) as defined in the American Thoracic Society/European Respiratory Society Statement, 2015

?. Patients with progressive lung fibrosis associated with different disorders (c) such as systemic connective tissue diseases, chronic fibrosin hypersensitivity pneumonitis (HP), idiopathic non-specific interstitial pneumonia (iNSIP) or sarcoidosis.

Disease progression will be established based on a combination of criterion (I)(a) and criterion (II) or criterion (III)(b)

I. Clinically significant decrease in FVC% predicted defined as absolute decrease of = 5% within 12 months prior to screening or an absolute decrease DLCO (corrected for hemoglobin) of =10% predicted within 12 months prior to screening.

II. Worsening respiratory symptoms without an alternative explanation within 12 months prior to screening.

III. Increased area affected with fibrosis on chest HRCT (b) (according to the 2022 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines) within 24 months prior to screening.

1. To assess this criterion (I), patient's pulmonary function test (PFT) results obtained within 12 months prior to screening must available. If data from multiple PFTs are available, the earliest results must be used for assessment.

2. Patients' results of at least one chest HRCT investigation performed no earlier than 24 months before randomization must be available for review. If results of multiple HRCT examinations are available, patient eligibility must be based on the earliest results.

3. stable course of the main disease not requiring a change in maintenance treatment.

3. ILD duration of no more than 5 years from the onset of respiratory symptoms by the date screening begins.

4. Elevated acute phase reactants at screening not related to other causes:

C-reactive protein level =6 mg/l or Erythrocyte Sedimentation Rate (ESR) =28 millimeters per hour (mm/hour).

5. FVC = 45% and = 80% predicted at screening.

Exclusion Criteria:

1. Hemoglobin-corrected DLCO < 40% predicted at screening.

2. Significant airway obstruction at screening defined as a Forced expiratory volume in 1 second (FEV1) / FVC ratio of <70 %.

3. Use of interleukin-6(IL-6 )inhibitors or IL-6 receptor inhibitors except for CoronaVirus Disease2019 (COVID-19) treatment. If those medications are used to treat COVID-19, the last administration of IL-6 inhibitors or IL-6 receptor inhibitors must have occurred at least 6 months prior to screening.

4. Administration of rituximab within less than 12 months prior to screening.

5. Treatment with systemic glucocorticosteroids (GCS) at >10 mg/day calculated for prednisolone; or a change in the dose of GCS within 4 weeks before/during the screening period; or planned dose changes during the trial.

6. A history of bone marrow transplantation, total lymphoid tissue irradiation, or administration of ablative ultra-high doses of cyclophosphamide.

7. Initiation of mycophenolate mofetil or antifibrotic agents (for patients receiving mycophenolate mofetil and/or antifibrotics at study entry) less than 12 months prior to screening.

8. Discontinuation of previously prescribed antifibrotic agents within 6 months prior to screening (for patients not receiving antifibrotic drugs at study entry).

9. Participation in any other clinical trial less than 30 days prior to the baseline assessment or less than 5 half-lives of the medication examined in another clinical trial, whichever is longer.

10. Laboratory abnormalities as follows:

• Alanine Aminotransferase (ALT) or Aspartate Aminotransferase(AST) = 1.5×Upper Limit Normal (ULN)

• Platelet count <100×10^9/litre (l) (<100000/cubic millimetre (mm^3)

• Leukocyte count <3.5×10^9/l

• Absolute neutrophil count <2000×10^6/l (<2000/mm^3).

11. Concurrent malignancy or a history of malignancy within the last 5 years.

12. Any acute infection at screening or exacerbation of a chronic infection, any infection requiring oral antibiotics or antivirals within 4 weeks prior to screening, injection of antimicrobial agents within 6 weeks before randomization, severe or recurrent infections requiring hospital admission within 6 months before randomization.

13. Patients with evidence of disseminated herpes zoster infection, herpes zoster with encephalitis, meningitis, or other forms of herpes zoster infection that do not resolve without treatment and occurred within 6 months prior to screening.

14. Evidence of any other chronic infection (including sepsis, invasive fungal infection, histoplasmosis, osteomyelitis) which, in the opinion of the Investigator, may increase the risk of infectious complications during the trial.

15. Patients with diverticulitis or other symptomatic gastrointestinal diseases that may lead to perforation, including such history (for example, diverticulitis, gastrointestinal perforation, ulcerative colitis).

16. Women of child-bearing potential or men whose partners are women of child-bearing potential who do not want to use highly effective methods of contraception during the trial and for at least 3 months after the last administration of the investigational product.

17. Known hypersensitivity to OKZ or any other component of the product or placebo.

18. History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies.

19. Other protocol-defined exclusion criteria apply.

Related Conditions & MeSH terms

• Lung Diseases
• Lung Diseases, Interstitial

Intervention

Drug:
• Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)
Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.
• SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL
Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.

Locations

Country	Name	City	State
Russian Federation	Chelyabinsk Regional Clinical Hospital	Chelyabinsk
Russian Federation	Regional Clinic Hospital?3	Chelyabinsk
Russian Federation	LLC" Medsi-Izhevsk"	Izhevsk
Russian Federation	Kuzbass Clinical Hospital Emergency Medical Care named after Podgorbunsky M.A	Kemerovo
Russian Federation	City Clinical hospital ?52	Moscow
Russian Federation	City Clinical Hospital named after Davydovsky I.V.	Moscow
Russian Federation	City Clinical Hospital named after Pletnev D.D.	Moscow
Russian Federation	Clinical Hospital ?3 of Sechenov University	Moscow
Russian Federation	Clinical Hospital ?4 of Sechenov University	Moscow
Russian Federation	FSBEI HE "Russian University of Medicine", MoH of Russia	Moscow
Russian Federation	Moscow City Clinic ?52	Moscow
Russian Federation	Moscow Regional Research and Clinical Institute "MONIKI"	Moscow
Russian Federation	Scientific Research Institute of Reumatology named after Nasonova V.A	Moscow
Russian Federation	Federal Research Center Institute of Cytologyand Genetics,Siberian Branch of Russian Academy of Sciences	Novosibirsk
Russian Federation	Republican Hospital named after V.A. Baranov	Petrozavodsk
Russian Federation	City Multidisciplinary Hospital ?2-Expert Center in the field of Pulmonology	Saint Petersburg
Russian Federation	LLC"Energy of Health"	Saint Petersburg
Russian Federation	LLC"Kurator"	Saint Petersburg
Russian Federation	LLC"My Medical Center"	Saint Petersburg
Russian Federation	Medical Center "Interleukin"	Saint Petersburg
Russian Federation	Pavlov First Saint Petersburg State Medical University(Pavlov University)	Saint Petersburg
Russian Federation	Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation	Saint Petersburg
Russian Federation	Clinical Hospital of Emergency Medical Care named after Solovyov N.V	Yaroslavl

Sponsors (5)

Lead Sponsor	Collaborator
R-Pharm International, LLC	Data Management 365, Exacte Labs LLC, Keystat, LLC, R-Pharm

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The rate of forced vital capacity (FVC)	FVC decline rate assessed over 48 weeks of therapy. FVC is the maximum amount of air that can be exhaled when blowing out as fast as possible.	48 weeks
Secondary	Change in FVC from baseline	Absolute change in FVC from baseline at treatment weeks 24 and 48.	24, 48 weeks.
Secondary	Change in FVC.% predicted	Change in FVC% predicted from baseline at treatment weeks 24 and 48.	24,48 weeks
Secondary	Number of patients (in %) with a decrease in FVC	Number of patients (in %) with a decrease in FVC of =10 % predicted.at treatment week 48.	48 weeks
Secondary	Number of patients (in %) with improved pulmonary function	Number of patients (in %) with improved pulmonary function (change from baseline in FVC >0% predicted.	48 weeks
Secondary	Change of Diffusing capacity of the lungs for carbon monoxide (DLCO)	Change in absolute values of DLCO from baseline at treatment weeks 24 and 48.	24,48 weeks
Secondary	Change in the values of quantitative assessment of lung fibrosis from baseline	Change in the values of quantitative assessment of lung fibrosis from baseline based on high-resolution computed tomography (HRCT) data at treatment week 48.	48 weeks
Secondary	Proportion of patients with progression or death	Proportion of patients with progression or death: the first event defined as death.; Progression is a decrease in FVC =10% predicted, or decrease in DLCO =15% predicted from their baseline values.	48 weeks
Secondary	Time to progression or death assessed over 48 weeks of treatment	Time to progression or death assessed over 48 weeks of treatment.	48 weeks
Secondary	Time to exacerbation over 48 weeks of treatment	An exacerbation of idiopathic lung fibrosis and other ILDs is defined as worsening shortness of breath over the past 30 days combined with evidence of new bilateral lesions appearing as ground-glass opacities and/or consolidations on a chest HRCT scan without other alternative causes (infections and other).	48 weeks
Secondary	Proportion of patients with exacerbation at treatment weeks 24 and 48	Proportion of patients with exacerbation over 48 weeks of treatment.	24,48 weeks
Secondary	Change in Functional Assessment of Chronic Illness Therapy (FACIT)-Dyspnea scores from baseline at treatment weeks 24 and 48	FACIT-Dyspnea questionnaire includes Dyspnea subscale, that measures the severity of dyspnea when doing everyday activities, and Functional Limitations subscale that measures the amount of difficulty experienced while doing these activities due to dyspnea in the past 7 days. Both subscales contain 10 items scored from 0 (best) to 4 (worst).; A raw score (normal-worst range 0-30) is calculated as: Sum individual item scores * 10 / number of items answered. Raw scores are then converted to scale scores using the table included in the FACIT Dyspnoea Scale Short Form Scoring Guideline.; Scale score range: Dyspnea subscale from 27.7 (normal condition) to 75.9 (severe symptoms); Functional Limitations subscale from 29.7 (not limited) to 76.7 (severely limited)	24,48 weeks
Secondary	Change in Short Form-36 (SF-36) scores from baseline at treatment weeks 24 and 48	36-Item Short-Form Health Survey (SF-36) is a patient reported survey of health consisting of 36 items that taps eight health concepts (domains): vitality; physical functioning; bodily pain; general health perceptions; physical role functioning; emotional role functioning; social role functioning; mental health. It also includes a single item that provides an indication of perceived change in health. For each domain a scaled score is calculated as the weighted sum of the questions in this section. Each scale is directly transformed into a 0 to 100 scale on the assumption that each question carries equal weight. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.	24,48 weeks
Secondary	Change in Modified Medical Research Council ( mMRC) dyspnea score from baseline at treatment weeks 24 and 48	Modified Medical Research Council (mMRC) Dyspnea Scale is used to assess perceived degree of baseline functional disability due to dyspnea. Participants indicate a score on 5-point scale according to the severity of their symptoms: none = 0; mild = 1; moderate = 2; severe =3; very severe = 4	24,48 weeks